Loading...

UNCY UNICYCIVE THERAPEUTICS INC Management Changes 8-K Filing

NCYC

NCY

UNICYCIVE THERAPEUTICS INC

(UNCY)

2025 8-K

Share Offering Increase

Financial Results Update

Financial Update

Lawsuit Notification

Stock Sale Report

Financial Results Update

Regulatory Compliance

Clinical Trials

Management Changes

Earnings Releases

Capital Structure Update

Financial Results

Nasdaq Compliance Notice

Financial Results

Nasdaq Compliance

Financial Results

Agreement with Shilpa Medic...

Clinical Trial Results

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Private Placement

Exchange Agreement and Cert...

Compliance Notice from Nasdaq

Earnings Reports

FDA Alignment on Oxylanthan...

Change in Accounting Firm

Earnings Reports

Resignation of Auditor

Compliance Regained

Update on New Drug Application

Annual Meeting of Stockholders

Financial Results Announcement

Amendment to Securities Pur...

Financial Results Announcement

Compliance with Nasdaq List...

Securities Purchase Agreement

Compliance Notice from Nasdaq

License Agreement with Lotu...

External Links:

On October 28, 2025, Unicycive Therapeutics, Inc. announced preliminary unaudited financial results showing approximately $42 million in cash as of September 30, 2025, and provided an update on their New Drug Application process after receiving feedback from the FDA on June 30, 2025.

AI Assistant

UNICYCIVE THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.